ResearchDx
YOUR COMPANION IN DIAGNOSTICS ®
ResearchDx
  • BIOPHARMA SERVICES
    • BioPharma Services
    • Biomarker Discovery & Validation
    • Immunotherapy Biomarkers
    • Liquid Biopsy Cancer Screening
    • Flow Cytometry Services
    • Polymerase Chain Reaction Lab
    • Next Generation Sequencing Services
    • Stratification in Clinical Trials
  • FDA COMPANION DIAGNOSTICS
    • FDA-Approved Companion Diagnostics
    • IVD Compliance
    • Clinical Trial Consulting
    • Orthogonal Validation
  • IVD
    • IVD
    • GMP Manufacturing
    • GLP Compliance
  • CLINICAL LAB CONSULTING
    • Clinical Laboratory Consulting
    • CLIA Lab
  • RESOURCES
    • Articles and Publications
    • News/Blog
    • Tradeshows/Events
    • FAQ
  • ABOUT
    • Management
    • Company
    • What is a CDO?
    • Our Lab
      • Protected Health Information
    • CAREERS
  • CONTACT

Opportunities to advance personalized medicine may be lost due to complexities in the development process. As the first CDO, we are committed to helping biopharmaceutical companies deliver regulatory-approved companion diagnostics that can impact the future of how medicine will be practiced.

Our Company

Company Location ResearchDxFounded in 2008, Philip D. Cotter, PhD and Mathew W. Moore, PhD established ResearchDx as the first, novel diagnostics business model to integrate and manage all IVD diagnostic development expertise and services within a single organization. This decision was driven by the accelerating demands of personalized medicine and the need for a simpler path for aligned development and regulatory approval of a therapeutic and its companion diagnostic.

Schedule a consultation with our research team to discuss your specific needs.

Although pharmaceutical companies have well-established pathways for drug development, none exist for the co-development of FDA-approved companion diagnostics. In order to acquire the diagnostics expertise needed, biopharma must either outsource to multiple vendors or a large diagnostic company. If they outsource to multiple vendors, they must manage a complex process that is neither flexible nor dynamic. If they outsource to a large diagnostic company, diagnostic development will be limited to the company’s existing technology, product lines, and platforms, which may not be best suited for the companion diagnostic. The choice of platform also affects deployment in the clinical laboratories that may offer the test.

The ResearchDx business model reduces an over-burdensome process by virtue of its organizational structure without competing interests and allows for consideration of emerging molecular technologies in the development process.

ResearchDx Today

Customized or “genomic” therapeutics have become the focus for pharmaceutical discovery, generating the need for matching companion diagnostics. As a full-service diagnostics organization, we offer a ‘start-finish’ partnership for the co-development of companion diagnostics. Providing independent and unbiased guidance, we design, manage and coordinate all aspects of the diagnostics development process, concept through regulatory approval, based on your goals and objectives. As a single outsourcing partner, we provide a flexible process that is adaptable to changing needs, priorities, and schedules.

Supported by our fully-accredited clinical laboratory PacificDx, ResearchDx offers a comprehensive range of services and specialty consulting for all diagnostic and co-development project needs.

Company ResearchDx

©2021 ResearchDx | Privacy | Site Map

ResearchDX
5 Mason, Irvine, CA 92618
info@researchdx.com
P: (866) 225-9195
F: (949) 297-3984

CONTACT US

  • Twitter
  • LinkedIn
ResearchDx
Top
  • Twitter
  • LinkedIn
YOUR COMPANION IN DIAGNOSTICS ®
Click to access the login or register cheese